Börger Ann-Kathrin, Eicke Dorothee, Wolf Christina, Gras Christiane, Aufderbeck Susanne, Schulze Kai, Engels Lena, Eiz-Vesper Britta, Schambach Axel, Guzman Carlos A, Lachmann Nico, Moritz Thomas, Martin Ulrich, Blasczyk Rainer, Figueiredo Constança
Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.
REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.
Mol Med. 2016 Sep;22:274-285. doi: 10.2119/molmed.2015.00235. Epub 2016 May 16.
Platelet (PLT) transfusion is indispensable to maintain homeostasis in thrombocytopenic patients. However, PLT transfusion refractoriness is a common life-threatening condition observed in multitransfused patients. The most frequent immune cause for PLT transfusion refractoriness is the presence of alloantibodies specific for human leukocyte antigen (HLA) class I epitopes. Here, we have silenced the expression of HLA class I to generate a stable HLA-universal induced pluripotent stem cell (iPSC) line that can be used as a renewable cell source for the generation of low immunogenic cell products. The expression of HLA class I was silenced by up to 82% and remained stable during iPSC cultivation. In this study, we have focused on the generation of megakaryocytes (MK) and PLTs from a HLA-universal iPSC source under feeder- and xeno-free conditions. On d 19, differentiation rates of MKs and PLTs with means of 58% and 76% were observed, respectively. HLA-universal iPSC-derived MKs showed polyploidy with DNA contents higher than 4n and formed proPLTs. Importantly, differentiated MKs remained silenced for HLA class I expression. HLA-universal MKs produced functional PLTs. Notably, iPSC-derived HLA-universal MKs were capable to escape antibody-mediated complement- and cellular-dependent cytotoxicity. Furthermore, HLA-universal MKs were able to produce PLTs after transfusion in a mouse model indicating that they might be used as an alternative to PLT transfusion. Thus, produced low immunogenic MKs and PLTs may become an alternative to PLT donation in PLT-based therapies and an important component in the management of severe alloimmunized patients.
血小板(PLT)输注对于维持血小板减少症患者的内环境稳定至关重要。然而,血小板输注无效是多次输血患者中常见的危及生命的情况。血小板输注无效最常见的免疫原因是存在针对人类白细胞抗原(HLA)I类表位的同种抗体。在此,我们沉默了HLA I类的表达,以生成一种稳定的HLA通用诱导多能干细胞(iPSC)系,该细胞系可作为可再生细胞来源,用于生成低免疫原性细胞产品。HLA I类的表达被沉默了高达82%,并且在iPSC培养过程中保持稳定。在本研究中,我们专注于在无饲养层和无异种条件下从HLA通用iPSC来源生成巨核细胞(MK)和血小板。在第19天,分别观察到MK和血小板的分化率,平均值分别为58%和76%。HLA通用iPSC来源的MK显示出多倍体,DNA含量高于4n,并形成前血小板。重要的是,分化的MKs的HLA I类表达仍然沉默。HLA通用的MKs产生了功能性血小板。值得注意的是,iPSC来源的HLA通用MKs能够逃避抗体介导的补体和细胞依赖性细胞毒性。此外,HLA通用的MKs在小鼠模型中输血后能够产生血小板,这表明它们可能用作血小板输注的替代品。因此,所产生的低免疫原性MKs和血小板可能成为基于血小板的治疗中血小板捐献的替代品,以及严重同种免疫患者管理中的重要组成部分。